Explore /
Poster
/ A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).

A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).

Authors

Hewitt Chang

University Of California, San Francisco, San Francisco, CA;

Hewitt Chang , Luchia Andemicael , Moshiur Mekhail Anwar , John Gordan , Jamese Johnson , Bridget P Keenan , Robin Kate Kelley , Andrew H. Ko , Katherine Van Loon , Alan P. Venook , Lawrence Fong , Melody Ju Xu , Mary Uan-Sian Feng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04221893

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS817)

DOI

10.1200/JCO.2023.41.4_suppl.TPS817

Abstract #

TPS817

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Gastrointestinal Cancers Symposium

$Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.$